As we enter into the final months of 2024, new developments in the administration of the 340B Drug Pricing Program signal that additional reform may be on the way. Although recent revisions to the 340B program’s...more
9/18/2024
/ Compliance ,
Consumer Protection Act ,
Dispute Resolution ,
Drug Pricing ,
Healthcare Reform ,
HRSA ,
Pharmaceutical Industry ,
Pharmacies ,
PHRMA ,
Prescription Drugs ,
Section 340B ,
Unfair or Deceptive Trade Practices
A Virginia Federal Judge recently rejected a challenge to a negative Advisory Opinion issued by the Department of Health & Human Services’ Office of Inspector General (OIG) that disapproved of a proposal where certain...more